“I read in the newspaper I’m both micromanaging every single thing in the FDA and I’m never there,” Vinay Prasad said.Courtesy FDA

Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing to STAT’s industry-leading events.

Lizzy Lawrence leads STAT’s coverage of the Food and Drug Administration. She was previously a medical devices reporter. You can reach Lizzy on Signal at lizzylaw.53.

NEW YORK — Vinay Prasad, the Food and Drug Administration’s top vaccines regulator, blamed “misleading media narratives” for the escalating criticism of his leadership amid turmoil and plummeting morale at the agency.

Prasad’s remarks, delivered Thursday at a New York investor conference closed to the public and press, came a day after 12 former FDA commissioners published an urgent warning that his proposed changes to vaccine policy would have dire consequences for American public health. 

Advertisement

Prasad, director of the Center for Biologics Evaluation and Research as well as the agency’s chief medical and scientific officer, defended his plan, which would require manufacturers to conduct longer and larger studies before updating vaccines, as a matter of modernizing FDA policy. “We’re not talking about throwing the baby out with the bathwater,” Prasad said of the proposal, which was detailed in a leaked memo to agency staff last month.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe